Scientists develop one-product-fits-all immunotherapy for pancreatic cancer

Pancreatic cancer is among the deadliest forms of cancer, with most patients diagnosed after the disease has already spread throughout the body. The five-year survival rate for metastatic cases hovers around 2–3%, and median survival is often…

Continue Reading


News Source: medicalxpress.com

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *